Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

“On the credibility scale, the company is a 9 and the skeptics here are a zero.“

You’re entitled to believe what you want but if what you say were true the stock would be $50 instead of $5. The fact is that many people with no particular agenda have questioned Anavex’s reported results and remain deeply skeptical. One need only look at how the stock reacted after and since last year’s CTAD debacle as evidence. While it’s true that biotech stocks generally have been weak for quite a while, AVXL’s dismal performance since CTAD 2022 goes well beyond the XBI.

Good luck and DOG bless.